Pull Controversial Drug from Market, Say Some FDA Staff

Avandia should be pulled from the market because of the "serious" cardiovascular risk the diabetes drug poses, which exceeds that of competitor Actos, according to some FDA staff reviewers. Avandia is no more effective at improving glycemic control in type 2 diabetes compared with Actos, and provides no known unique health benefits. While both drugs increase the risk of congestive heart failure, Avandia's effect on CHF is "substantially greater," FDA reviewers wrote in a massive briefing...Full Story
Commenting on this article is closed.